Phanes Therapeutics Doses First Patient in Peluntamig Study for SCLC and NEC
Sino-US biotech Phanes Therapeutics Inc. announced that the first patient has been dosed in a...
Clinical trial approval / initiation
Hepalink Pharmaceutical’s H1710 Heparanase Inhibitor Approved for Phase I Study
China-based Shenzhen Hepalink Pharmaceutical Group Co., Ltd (SHE: 002399) announced that it has received approval...
Hanx Biopharmaceuticals’ HX009 Receives NMPA Clearance for TNBC Study
Hanx Biopharmaceuticals (Wuhan) Co., Ltd. announced that it has received clearance from the National Medical...
Biokin Pharmaceutical’s BL-M07D1 Receives NMPA Approval for Phase II/III Study in HER2+ Breast Cancer
China-based Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506) announced that it has received approval from...
InnoCare Pharma Receives NMPA Approval for Mesutoclax Phase III Study in CLL/SLL
Beijing-based biotech InnoCare Pharma (HKG: 9969, SHA: 688428) announced that it has received approval from...
Gan & Lee Pharmaceuticals Doses First Patient in GZR4 Phase III Study for Diabetes
China-based Gan & Lee Pharmaceuticals (SHA: 603087) announced that the first patient has been dosed...
Zelgen Biopharmaceuticals’ ZG005 Bispecific Antibody Receives NMPA Approval for Biliary Tract Cancer Trials
China-based Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) announced that it has received clinical trial...
Biokin Pharmaceutical Registers Phase III Study for BL-B01D1 in EGFR Mutant NSCLC
Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506) has registered a Phase III study on chinadrugtrials.org.cn...
Kexing Biopharm’s GB05 Receives FDA Approval for Pediatric RSV Infections
China-based Kexing Biopharm Co., Ltd. (SHA: 688136) announced that it has received clinical trial approval...
Konruns Pharmaceutical’s KC1036 Enters Phase II Trial for Ewing’s Sarcoma in Adolescents
Beijing-based Konruns Pharmaceutical Co., Ltd (SHA: 603590) announced the first patient dosing in a Phase...
Hengrui’s Vunakizumab Receives NMPA Approval for nr-axSpA Treatment
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced that it has received another clinical trial...
Accropeutics Doses First Patient in AC-101 Phase Ib UC Study
Accro Bioscience (Suzhou) limited, better known as Accropeutics, a clinical-stage biotech operating out of New...
Livzon Pharmaceutical’s JP-1366 Approved for Peptic Ulcer Study by NMPA
China-based Livzon Pharmaceutical Group Inc. (HKG: 1513) has obtained approval from the National Medical Products...
Lion TCR’s Liocyx-M00 Therapy Receives FDA Clearance for HBV-Related HCC Study
Singapore-based clinical-stage biotechnology company Lion TCR, backed by Chinese investors, has received clearance from the...
Degron Therapeutics’ DEG6498 Receives FDA Clearance for Clinical Trials
China-based Degron Therapeutics, a developer of molecular glue-based drugs, announced that the U.S. Food and...
Bio-Thera Solutions’ BAT1006 Wins NMPA Approval for HER2+ Breast Cancer Trial
China’s Bio-Thera Solutions Ltd (SHA: 688177) has received clinical trial approval from the National Medical...
Henlius Biotech’s HLX99 Receives FDA Approval for ALS Clinical Study
Shanghai Henlius Biotech Inc. (HKG: 2696) announced that the U.S. Food and Drug Administration (FDA)...
Henlius Biotech Doses First Patient in HLX43 Phase II Study for Esophageal Cancer
Shanghai Henlius Biotech Inc. (HKG: 2696) announced the first patient dosing in a Phase II...
CSPC Pharmaceutical’s SYH2039 Wins FDA Clinical Approval for Advanced Tumors
China’s CSPC Pharmaceutical Group Ltd (HKG: 1093) announced that the U.S. Food and Drug Administration...
Changchun GeneScience’s GenSci120 Receives NMPA Approval for Rheumatoid Arthritis Trials
China-based Changchun GeneScience Pharmaceutical Co., Ltd announced that it has received another clinical trial approval...